Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Canagliflozin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Indoco's ANDA for Canagliflozin, Metformin Gets Tentative Approval
Details : Invokamet-Generic (canagliflozin and metformin HCl) T is a SGLT2 inhibitor & biguanide combination product indicated for the treatment of adults with type 2 diabetes mellitus.
Brand Name : Invokamet-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 06, 2024
Lead Product(s) : Canagliflozin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Canagliflozin inhibits SGLT2 which reduces reabsorption of filtered glucose thereby increases urinary glucose excretion. Metformin decreases hepatic glucose production, intestinal absorption of glucose and improves insulin sensitivity.
Brand Name : Canagliflozin/Metformin Hydrochloride-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 20, 2023
Lead Product(s) : Canagliflozin,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives USFDA Tentative Approval For Canagliflozin Tablet
Details : Canagliflozin Tablet is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Brand Name : Canagliflozin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2023
Lead Product(s) : Canagliflozin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Janssen Scientific Affairs
Deal Size : Not Applicable
Deal Type : Not Applicable
Heart Failure Symptoms Improved with A Type 2 Diabetes Medicine in Fully Remote Trial
Details : Adults with heart failure who took canagliflozin, a medication originally developed to treat type 2 diabetes, reported improvements in their heart failure symptoms whether or not they also had type 2 diabetes.
Brand Name : JNJ-28431754
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2021
Lead Product(s) : Canagliflozin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Janssen Scientific Affairs
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Tai Tien Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Canagliflozin (TA-7284) has Been Approved in Taiwan For Diabetic Nephropathy
Details : Tai Tien Pharmaceuticals has obtained the regulatory approval of CANAGLU® (CANAGLU)(INN: canagliflozin; Japan names: CANAGLU® Tablets 100mg) for a treatment agent for diabetic nephropathy in Taiwan FDA.
Brand Name : Canaglu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 26, 2021
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Tai Tien Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The EC approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which achieved pre-specified efficacy criterion.
Brand Name : Invokana
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 03, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The European Commission approval is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on the achievement of a pre-specified efficacy c...
Brand Name : Invokana
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Positive opinion is based on the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation Phase III renal outcomes trial, which was stopped early based on a conclusive signal of efficacy in the prevention of the prim...
Brand Name : Invokana
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2020
Lead Product(s) : Canagliflozin
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?